Nuvation Bio Inc. is a biopharmaceutical company. It engages in developing differentiated and novel therapeutic candidates for unmet needs in oncology. Nuvation Bio Inc., formerly known as Panacea Acquisition Corp., is based in NEW YORK.
| Revenue (Most Recent Fiscal Year) | $7.87M |
| Net Income (Most Recent Fiscal Year) | $-567.94M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 107.28 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 8.81 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -813.07% |
| Net Margin (Trailing 12 Months) | -813.07% |
| Return on Equity (Trailing 12 Months) | -54.99% |
| Return on Assets (Trailing 12 Months) | -38.12% |
| Current Ratio (Most Recent Fiscal Quarter) | 8.48 |
| Quick Ratio (Most Recent Fiscal Quarter) | 8.39 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.14 |
| Inventory Turnover (Trailing 12 Months) | 7.80 |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.37 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.16 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.37 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.64 |
| Exchange | NYSE |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 342.83M |
| Free Float | 240.22M |
| Market Capitalization | $2.87B |
| Average Volume (Last 20 Days) | 9.80M |
| Beta (Past 60 Months) | 1.58 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 29.93% |
| Percentage Held By Institutions (Latest 13F Reports) | 61.67% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |